cagrilintide + semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ CAGRILINTIDE/SEMAGLUTIDE BLEND PEPTIDE (5MG/5MG) 10MG

MASLD (metabolic dysfunction-associated steatotic liver disease) is the new umbrella term adopted in 2023

The condition ranges from acute episodes to chronic progressive disease

Summary: There is no official contraindication preventing concurrent use of L-carnitine and Mounjaro, but no robust evidence demonstrates additional benefits from this combination

The primary analysis of PIONEER 2 and 3 was non-inferiority of semaglutide compared to empagliflozin and sitagliptin, respectively, in terms of change from baseline in A1C (%) at week 26

Several voting members work for or advise companies that stand to benefit commercially from peptide sales a conflict flagged by researchers and consumer-safety advocates

Possible Changes to Semaglutide Treatment If body aches are severe or persistent, your healthcare provider might adjust your semaglutide treatment: Dosage Adjustment: Lowering the dose can reduce side effects while maintaining benefits